Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Relay Therapeutics, Inc.
Report date July 20, 2020 · Filed July 21, 2020
Jointly reported with SHAW DAVID E
Section 16 reporting ended · disclosed 2020-07-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 3,281,253 |
Reported balance
After 2020-07-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-07-20 · Conversion · Acquired 3,281,253 · Balance 3,281,253 F1: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F3: David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any. |
| Series A Preferred Stock, $0.001 par value per shareSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-20 · Conversion · Disposed 9,999,999 · Balance 0 F1: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F3: David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any. |
| Series C Preferred Stock, $0.001 par value per shareSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-20 · Conversion · Disposed 1,651,471 · Balance 0 F2: Each share of Issuer Series C Preferred Stock, $0.001 par value per share, automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .2985366 of a share of Common Stock for each share of Series C Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F1: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F3: David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date.
F2: Each share of Issuer Series C Preferred Stock, $0.001 par value per share, automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .2985366 of a share of Common Stock for each share of Series C Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date.
F3: David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2020 Filed Jul 21, 2020 17:34 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | ConversionSeries C Preferred Stock, $0.001 par value per share · Derivative | 1,651,471 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019815 · doc4.xml · derivative · entry 3 Picularium, LLC · CIK 0001817110 · 10% owner SHAW DAVID E · CIK 0001023870 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock,$0.001 par value per share · 465,082 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Issuer Series C Preferred Stock, $0.001 par value per share, automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .2985366 of a share of Common Stock for each share of Series C Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F1 · derivative.exercise_date: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F1 · derivative.expiration_date: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F1 · derivative.underlying_shares: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F3 · ownership.direct: David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 17:34 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | ConversionSeries A Preferred Stock, $0.001 par value per share · Derivative | 9,999,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019815 · doc4.xml · derivative · entry 2 Picularium, LLC · CIK 0001817110 · 10% owner SHAW DAVID E · CIK 0001023870 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock,$0.001 par value per share · 2,816,171 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F1 · derivative.exercise_date: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F1 · derivative.expiration_date: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F1 · derivative.underlying_shares: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F3 · ownership.direct: David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 17:34 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | ConversionCommon Stock, par value $0.001 per share | 3,281,253 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019815 · doc4.xml · nonDerivative · entry 1 Picularium, LLC · CIK 0001817110 · 10% owner SHAW DAVID E · CIK 0001023870 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,281,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. F3 · ownership.direct: David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.